-->

Tag: Precision oncology breakthrough

Home / Precision oncology breakthrough

Categories

Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer

  June 2024: The Food and Drug Administration has given accelerated approval to adagrasib (Krazati; Mirati Therapeutics, Inc.) in combination with cetuximab for adults who have KRAS G12C-mutat...
precision-oncology-breakthrough

Belzutifan is approved by USFDA for advanced renal cell carcinoma

The Food and Drug Administration granted approval for belzutifan (Welireg, Merck & Co., Inc.) on December 14, 2023, for patients with advanced renal cell carcinoma (RCC) who have previously recei...
precision-oncology-breakthrough

Scan the code